GLG News in Healthcare

To stent or not to stent: presence and degree of coronary artery disease, effectiveness of medical therapy and significance of symptoms and, therefore, indications for coronary stents placement are determined by very same physicians who place stents. Stents are reimbursed 10-20 times better than medical management.

Electronic Medical Records (EMR) or Electronic Health Records (EHR) are the most modern formats emerging in the medical field thanks to the innovations emerging in Information Technology Segment.  Most of the current day patients are aware of medical attention needs unlike the olden past. However, the nuances of EMR are yet to be propagated by the medical fraternity or by the providers as such...

The co-marketing with Abbott will undoubtedly help Crestor sales, if they can effectively develop a fenofibrate-rosuvastatin combination, and avoid over-burdening physicians with reps. However, there are other factors that will probably have a larger impact. 

Given what happened to Galvus, and the similar poor selectivity of saxagliptin for DPP-4 over other isoforms, I think that FDA approval is unlikely. There was also some data on changes in white count presented at the ADA that will hurt this agent. The FDA move to recommend outcome studies for DM treatments may also hurt them.

This will probably help Byetta sales modestly. However, the numbers ere small, it was a non-randomized comparison, and may be that Byetta use was a surrogate for less sulfonurea use, lower doses of insulin or no insulin at all (any of which may be harmful). However, the main barrier to more widespread Byetta use is the need for BID injections and the training required. These data may provide more...

This study pretty convincingly shows that there is only a short term symptom and quality of life improvement associated with coronary stenting, as compared to good quality pharmacological treatment. This will decrease the pressure for aggressive revascularization of any and all coronary lesions (which has been pushed by many interventionalists). If the results are accepted by the health...

1) BiovaxID shows a 100% improvement in DFS at 3 years (p=0.24) 2) BiovaxID shows an improvement in median overall DFS with a significant P value (p=0.047) 2) This is the first lymphoma vaccine with a suggestion of activity. 3) BiovaxID shows evidence of activity despite the failure of 2 other lymphoma vaccines made by Genitiope and Favrille.

Very interesting results; Need more information. Did Janumet also result in weight loss? does weight loss disappear after a while? Was weight loss associated with an improvement in cardiovascular hemodynamics, lipid profile and elasticity of blood vessels; it will be interesting to see if the secondary features of diabetes mellitus will also be eliminated with Byetta. it will be interesting also to...

-Crestor sold 2.8 billion dollars in sales in the recent year, will this partnership result in long term exponential growth? -What are the implications for Crestor with generic simvastatin and with Lipitor going generic in the next few years? -Is a combination product going to bolster Crestor sales?

1.  Public awareness and budget for research for brain will increase. 2. Federal      funding  should increase for GBM ( Glioblastoma multiforme) 3. More researchers will join in this field